Multi-center, randomized, double-blind, phase III efficacy study comparing phenoxodiol in combination with carboplatin versus carboplatin with placebo in patients with platinum-resistant or platinum-refractory late-stage epithelial ovarian, fallopian or primary peritoneal cancer following at least second line platinum therapy.

Trial Profile

Multi-center, randomized, double-blind, phase III efficacy study comparing phenoxodiol in combination with carboplatin versus carboplatin with placebo in patients with platinum-resistant or platinum-refractory late-stage epithelial ovarian, fallopian or primary peritoneal cancer following at least second line platinum therapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Jul 2016

At a glance

  • Drugs Carboplatin; Idronoxil
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms OVATURE
  • Sponsors MEI Pharma
  • Most Recent Events

    • 14 Apr 2012 Planned number of patients changed from 340 to 470 as reported by European Clinical Trials Database record.
    • 03 Feb 2012 Additional lead trial investigator identifed as reported by ClinicalTrials.gov.
    • 03 Feb 2012 Actual end date (1 Apr 2011 ) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top